75N93024C00048
Definitive Contract
Overview
Government Description
VECTOR-BASED DELIVERY OF HIV BROADLY NEUTRALIZING ANTIBODIES
Awardee
Awarding / Funding Agency
Place of Performance
Newton Center, MA 2459 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Est. Average FTE
2
Related Opportunity
SBIRPHS20241
Cure Systems was awarded
Definitive Contract 75N93024C00048 (75N930-24-C-00048)
for Vector-Based Delivery Of Hiv Broadly Neutralizing Antibodies
worth up to $300,000
by the National Institute of Allergy and Infectious Diseases
in August 2024.
The contract
has a duration of 1 year and
was awarded
with a Small Business Total set aside
with
NAICS 541715 and
PSC AN12
via direct negotiation acquisition procedures with 7 bids received.
SBIR Details
Research Type
Small Business Innovation Research Program (SBIR) Phase I
Title
VECTOR-BASED DELIVERY OF HIV BROADLY NEUTRALIZING ANTIBODIES
Abstract
Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies: NIAID and its partners are building on the success of the Antibody Mediated Prevention (AMP) trials by engineering next-generation broadly neutralizing antibody (bNAb) candidates to enhance potency, increase tissue levels, extend half-life, and contend with the ever-evolving global diversity of HIV-1. Developing bNAb cocktails presents additional challenges: complex pharmacokinetics, larger injection volumes, multi-product formulations, and complicated manufacturing. The goal of this program is to support small businesses in the development of devices and/or materials for administration of HIV-1 bNAb(s) and bNAb derivatives (e.g., bispecific antibodies), resulting in increased protection from infection. The goal of this contract is to create optimized VIP-2.0 vectors that yield enhanced bNAb expression in vivo.
Research Objective
The goal of phase I is to establish the technical merit, feasibility, and commercial potential of proposed R&D efforts and determine the quality of performance of the small business awardee organization.
Topic Code
124
Agency Tracking Number
75N93024C00048-0-9999-0
Solicitation Number
PHS-2024-1
Contact
Status
(Complete)
Last Modified 9/30/24
Period of Performance
8/1/24
Start Date
7/31/25
Current End Date
7/31/25
Potential End Date
Obligations
$300.0K
Total Obligated
$300.0K
Current Award
$300.0K
Potential Award
Award Hierarchy
Definitive Contract
75N93024C00048
Subcontracts
Activity Timeline
Transaction History
Modifications to 75N93024C00048
People
Suggested agency contacts for 75N93024C00048
Competition
Number of Bidders
7
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
CV8RCUBHN248
Awardee CAGE
95LN8
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhszfetters
Last Modified By
hhsavirts
Approved By
hhsavirts
Legislative
Legislative Mandates
None Applicable
Performance District
MA-04
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Representative
Jake Auchincloss
Modified: 9/30/24